Skip to main content
. 2016 Apr 29;10(7):1063–1077. doi: 10.1016/j.molonc.2016.04.007

Figure 4.

Figure 4

The effects of BA on MUC4 expression via activation and nuclear translocation of c‐Jun. A. Sequence of the MUC4 distal promoter (P‐1641) which has two binding sites for c‐Jun protein (marked red). B. Graph showing increase in c‐Jun mRNA expression in a dose‐dependent manner in CD18/HPAF cell line, treated for 2 h with DCA and CDCA. C. CD18/HPAF and T3M4 cell lines were treated with BA (50 μM) for 4 h and cell lysates were collected. Immunoblot was performed to observe change in c‐Jun expression in DCA‐ and CDCA‐treated CD18/HPAF and T3M4 cell lines, compared to their respective untreated controls. D. Confocal images showing significant increase in c‐Jun and MUC4 protein expression in CD18/HPAF cells treated with DCA or CDCA. Graph showing the quantification of the c‐Jun positive nuclei in DCA and CDCA treated CD18/HPAF cells. E. Immunoblot showing significant increase in the expression levels of c‐Jun in the nuclear fraction obtained from BA (25 μM)‐treated CD18/HPAF cells, whereas cytoplasmic fraction did not demonstrate any noticeable alteration in c‐Jun expression. F. ChIP experiment was performed to observe the effect on enrichment for c‐Jun binding on MUC4 distal promoter in the presence or absence of DCA (50 μM) and CDCA (50 μM). We observed a significant increase in fold‐enrichment at both region‐I (containing two c‐Jun binding sites) and region‐II (containing one c‐Jun binding sites) (*p < 0.05, **p < 0.01, ***p < 0.001, scale bar = 20 μM).